Koichi Nishi

Koichi Nishi

Auto-generated profile, based on publicly available information

Koichi Nishi

Department of Respiratory Medicine, Ishikawa Prefectural Central Hospital, 2-1 Kuratsuki-Higashi, Kanazawa, Ishikawa, 920-8530, Japan

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2022 in Clinical Lung Cancer
Verified
Journal Article
Closed access
TYTaro Yoneda
Taro Yoneda
TSTakashi Sone
Takashi Sone
HKHayato Koba
Hayato Koba
KSKazuhiko Shibata
Kazuhiko Shibata
JSJunya Suzuki
Junya Suzuki
KKKazuo Kasahara
Kazuo Kasahara

4 February 2025 in Lung Cancer
Verified
Journal Article
Open access
YTYuichi Tambo
Yuichi Tambo
TSTakashi Sone
Takashi Sone
KNKoichi Nishi
Koichi Nishi
KSKazuhiko Shibata
Kazuhiko Shibata
TKToshiyuki Kita
Toshiyuki Kita
SYSeiji Yano
Seiji Yano
Use of pembrolizumab as first-line treatment in patients with non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥ 50 % was approved in Japan 5 years ago. We investigated the long-term efficacy and safety of this treatment in a real-world setting. This multicenter observational study enrolled 95 consecutive cases of histologically diagnosed advanced or recurrent NSCLC with a PD-L1 TPS score ≥ 50 %, who received pembrolizumab as first-line treatment between February 2017 and December 2018. Clinical data were collected from electronic medical records. PD-L1 TPS scores were assessed immunohistochemically, using the 22C3 antibody. The median follow-up period was 71.1 months. The median progression-free survival (PFS) was 6.9 months (95 % confidence interval [CI]; 4.7-9.1 months), and the 2-, 3-, and 5-year PFS rates were 24.9 %, 19.3 %, and 14.2 %, respectively. The median overall survival (OS) was 19.1 months (95 %CI; 13.3-24.9 months). The 2-, 3-, and 5-year OS rates were 42.7 %, 33.9 %, and 24.8 %, respectively. On multivariate analysis, histology (squamous vs. non-squamous cell carcinoma; hazard ratio [HR] 2.23, 95 %CI 1.40-3.89, p = 0.001) and number of metastatic sites (< 3 vs. ≥ 3; HR 4.65 95 %CI 2.51-8.62, p < 0.001) independently affected long-term survival. Immune-related adverse events occurred in 43 cases (45.3 %; 20 [21.0 %] Grade ≥ 3). The real-world 5-year survival rate of NSCLC cases with PD-L1 ≥ 50 % treated with first-line pembrolizumab was comparable to that in a clinical trial. Histological type and number of metastatic sites influenced long-term and 5-year survival.

30 August 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AIAzumi Ishizaki
Azumi Ishizaki
XBXiuqiong Bi
Xiuqiong Bi
QNQuynh Thi Nguyen
Quynh Thi Nguyen
TMTomomi Maeno
Tomomi Maeno
AHAkinori Hara
Akinori Hara
HIHiroshi Ichimura
Hiroshi Ichimura
This study aimed to elucidate the 12-month durability of neutralizing antibodies (NAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients infected during the 2020 workplace outbreaks of coronavirus disease 2019 (COVID-19) in Japan. We followed 33 Japanese patients infected with SARS-CoV-2 in April 2020 for 12 months (12M). Patients were tested for NAbs and for antibodies against the SARS-CoV-2 nucleocapsid (anti-NC-Ab) and antibodies against the spike receptor-binding domain (anti-RBD-Ab). Tests were performed at 2M, 6M, and 12M after the primary infection (api) with commercially available test kits. In 90.9% (30/33) of patients, NAbs persisted for 12M api, though the median titers significantly declined from 78.7% (interquartile range [IQR]: 73.0–85.0%) at 2M, to 59.8% (IQR: 51.2–77.9) at 6M (P = 0.008), and to 56.2% (IQR: 39.6–74.4) at 12M (P<0.001). An exponential decay model showed that the NAb level reached undetectable concentrations at 35.5 months api (95% confidence interval: 26.5–48.0 months). Additionally, NAb titers were significantly related to anti-RBD-Ab titers (rho = 0.736, P<0.001), but not to anti-NC-Ab titers. In most patients convalescing from COVID-19, NAbs persisted for 12M api. This result suggested that patients need a booster vaccination within one year api, even though NAbs could be detected for over two years api. Anti-RBD-Ab titers could be used as a surrogate marker for predicting residual NAb levels.

20 January 2023 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
KNKensuke Nakagawara
Kensuke Nakagawara
HKHirofumi Kamata
Hirofumi Kamata
SCShotaro Chubachi
Shotaro Chubachi
HNHo Namkoong
Ho Namkoong
HTHiromu Tanaka
Hiromu Tanaka
KFKoichi Fukunaga
Koichi Fukunaga

23 March 2024 in Respiratory Investigation
Verified
Journal Article
Open access
YIYoshihisa Ishiura
Yoshihisa Ishiura
MFMasaki Fujimura
Masaki Fujimura
HOHaruhiko Ogawa
Haruhiko Ogawa
JHJohsuke Hara
Johsuke Hara
HSHiromoto Shintani
Hiromoto Shintani
ANAkio Niimi
Akio Niimi
Chronic cough is one of the most common symptoms of respiratory diseases and can adversely affect patients' quality of life and interfere with social activities, resulting in a significant social burden. A survey is required to elucidate the frequency and treatment effect of chronic cough. However, clinical studies that cover all of Japan have not yet been conducted. Patients who presented with a cough that lasted longer than 8 weeks and visited the respiratory clinics or hospitals affiliated with the Japan Cough Society during the 2-year study period were registered. A total of 379 patients were enrolled, and those who did not meet the definition of chronic cough were excluded. A total of 334 patients were analyzed: 201 patients had a single cause, and 113 patients had two or more causes. The main causative diseases were cough variant asthma in 92 patients, sinobronchial syndrome (SBS) in 36 patients, atopic cough in 31 patients, and gastroesophageal reflux (GER)-associated cough in 10 patients. The time required to treat undiagnosed patients and those with SBS was significantly longer and the treatment success rate for GER-associated cough was considerably poor. We confirmed that the main causes of chronic cough were cough variant asthma, SBS, atopic cough, and their complications. We also showed that complicated GER-associated cough was more likely to become refractory. This is the first nationwide study in Japan of the causes and treatment effects of chronic cough.

6 December 2024 in Respiratory Investigation
Verified
Journal Article
Open access
YIYoshihisa Ishiura
Yoshihisa Ishiura
MFMasaki Fujimura
Masaki Fujimura
HOHaruhiko Ogawa
Haruhiko Ogawa
JHJohsuke Hara
Johsuke Hara
HSHiromoto Shintani
Hiromoto Shintani
ANAkio Niimi
Akio Niimi
Subacute cough is subdivided and distinguished from chronic cough, because post-infectious cough is considered to be the main cause of subacute cough and differs from acute and chronic cough. However, the details of the spectrum and frequency of causes of subacute cough remain unclear because only two studies on subacute cough have been published. Patients who presented with cough that lasted for 3-8 weeks and visited respiratory clinics or hospitals affiliated with the Japan Cough Society during 2 years were studied. A total of 148 patients were prospectively enrolled, and those who did not meet the definition of subacute cough were excluded. Ninety-seven (68.3%) patients with subacute cough progressed to chronic cough, and the main causative diseases were cough variant asthma in 44 patients, atopic cough in 24 patients, sinobronchial syndrome in 13 patients, and post-infectious cough in seven patients. Patients with cough variant asthma complicated by atopic cough and those in whom the cause of subacute cough was unknown tended to develop chronic cough. This study shows that post-infectious cough is less common than previously thought and the main causes of subacute cough are cough variant asthma, atopic cough, and sinobronchial syndrome and their complications. Cough variant asthma in combination with atopic cough also can be a precursor of refractory chronic cough. The careful diagnosis and treatment of two or more causative diseases is required in patients with subacute cough.